Eleven healthy volunteers were recruited upon informed and written consent. Two subjects had previously been vaccinated with pneumococcal vaccines (Table 2
Pneumovax 23
Manufactured by MSD
Pneumovax 23 is a pneumococcal polysaccharide vaccine. It is used to help prevent infections caused by pneumococcus bacteria.
Automatically generated - may contain errors
Lab products found in correlation
2 protocols using pneumovax 23
1
Pneumococcal Vaccine Immune Response
2
Comparative Analysis of Pneumococcal Vaccines
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
V114 (VAXNEUVANCE™, MSD) is a 15-valent PCV. Each 0.5 mL dose contains 2 µg of pneumococcal capsular polysaccharide from serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F, 22F, and 33F, and 4 µg of serotype 6B, all conjugated to CRM197 carrier protein and adjuvanted with 125 µg aluminum phosphate.
PCV13 (Prevnar 13©, Wyeth LLC, marketed by Pfizer, New York, NY, USA) is a 13-valent PCV. Each 0.5 mL dose contains 2.2 µg of pneumococcal capsular polysaccharide from serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, and 23F, and 4.4 µg of serotype 6B, all conjugated to CRM197 carrier protein and adjuvanted with 125 µg aluminum phosphate.
PPSV23 (PNEUMOVAX® 23, MSD) is a 23-valent pneumococcal polysaccharide vaccine. Each dose of PPSV23 contains 25 µg of pneumococcal capsular polysaccharide from serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F.
V114 and PCV13 were supplied as sterile suspensions and PPSV23 was supplied as a sterile solution. All study vaccines were supplied in pre-filled syringes and stored at 2–8 °C. A 0.5 mL dose of V114 (lot number 00068290) or PCV13 (lot numbers 0000793304, 0000921112, and 0000814723) and PPSV23 (lot number 0000794346) was administered intramuscularly using needles suited for intramuscular injection.
PCV13 (Prevnar 13©, Wyeth LLC, marketed by Pfizer, New York, NY, USA) is a 13-valent PCV. Each 0.5 mL dose contains 2.2 µg of pneumococcal capsular polysaccharide from serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, and 23F, and 4.4 µg of serotype 6B, all conjugated to CRM197 carrier protein and adjuvanted with 125 µg aluminum phosphate.
PPSV23 (PNEUMOVAX® 23, MSD) is a 23-valent pneumococcal polysaccharide vaccine. Each dose of PPSV23 contains 25 µg of pneumococcal capsular polysaccharide from serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F.
V114 and PCV13 were supplied as sterile suspensions and PPSV23 was supplied as a sterile solution. All study vaccines were supplied in pre-filled syringes and stored at 2–8 °C. A 0.5 mL dose of V114 (lot number 00068290) or PCV13 (lot numbers 0000793304, 0000921112, and 0000814723) and PPSV23 (lot number 0000794346) was administered intramuscularly using needles suited for intramuscular injection.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!